Table 2 Frequency and severity of adverse events

From: Safety and immunogenicity of an HIV vaccine trial with DNA prime and replicating vaccinia boost

 

Ia

Ib

rTV-L (n = 6)

rTV-H (n = 6)

DNA-L/rTV (n = 12)

DNA-H/rTV (n = 12)

DNA (n = 6)

Placebo (n = 6)

Any AE

6 (100%)

6 (100%)

10 (83%)

11 (92%)

4 (67%)

4 (67%)

 Relateda

4 (67%)

5 (83%)

7 (58%)

7 (58%)

2 (33%)

1 (17%)

 Grade 3

0 (.)

1 (17%)

1 (8%)

1 (8%)

2 (33%)

0 (.)

Any SAE

0 (.)

0 (.)

0 (.)

0 (.)

0 (.)

0 (.)

Any AE leading to withdrawal

0 (.)

0 (.)

0 (.)

0 (.)

0 (.)

0 (.)

  1. All data are n (%)
  2. AE adverse event, SAE serious adverse event
  3. aThe adverse event definitely, probably, or possibly related to study vaccine or vaccination considered by the investigators
Back to article page